a simple and useful diagnostic tool in daily clinical practice. 7 However, using a single colonoscopic evaluation for the differentiation between CD and ITB has inherent limitations because certain types of disease, such as small bowel CD, only present with lesions beyond the reach of a colonoscope. Moreover, certain characteristic endoscopic features for CD and ITB might be less obvious in the mild or early stages of the diseases.
For more precise differential diagnosis, multiple diagnostic modalities, such as clinical symptoms and colonoscopic, laboratory, radiologic, and pathologic features, must be combined. Clinical symptoms, however, are subjective and can be influenced by recall bias because of an extended time lag between symptom development and diagnosis. Microbiological evaluations, such as acid-fast bacilli (AFB) and positive culture for Mycobacterium tuberculosis (MTB), can be useful for differential diagnosis, but the findings have low sensitivity and the process is time consuming. 2, 9 Furthermore, some pathologic parameters, such as the number or size of granulomata and focally enhanced colitis, require meticulous interpretation of biopsy specimens by specialized pathologists. 1, 3, 10 Therefore, a prediction model using more objective yet convenient parameters could be useful in clinical practice.
The aim of this prospective study was to validate whether the colonoscopic scoring system by Lee et al 7 is still useful 10 years after its development and to determine the distinguishing laboratory and radiologic features of CD and ITB. In addition, we evaluated the diagnostic value of combining laboratory and radiologic parameters with colonoscopic factors and developed a practical prediction model to accurately differentiate between CD and ITB.
METHODS

Patients
The study of Differential dIAGnosis between CrohN's disease and intestinal tuberculOSIS (DIAGNOSIS) was a singlecenter prospective study conducted from June 2011 to February 2015, and follow-up for enrolled patients was ended in September 2016. This study was approved by the Institutional Review Board of the Asan Medical Center (IRB No. 2011-0380), and informed consent was obtained from all participants. All clinical data and samples were obtained with written informed consent under institutional review board-approved protocols.
All patients suspected of having CD or ITB based on clinical history, symptoms, and/or colonoscopic findings were screened and invited to participate in the study. Exclusion criteria were a refusal to participate in the study; being younger than 15 years; comorbidity with acute infectious disease; pregnancy; history of medication including anti-TB drugs, immunosuppressive drugs, and chemotherapeutic agents; or use of antibiotics within the past 3 months. After protocol-based colonoscopic, laboratory, and radiologic evaluation, cases with definite CD or ITB were finally enrolled in the development group for a new prediction model (40 patients newly diagnosed with CD and 40 newly diagnosed with ITB). Next, we enrolled an additional 37 patients (14 patients newly diagnosed with CD and 23 with ITB) for validation of our developed model (validation group). The final diagnostic criteria for CD and ITB were previously described in a detailed manner. 7 
Study Design
The study was constructed in 3 steps as follows: step 1, validation of the previous colonoscopic scoring system for the differential diagnosis of CD and ITB (the development group; 40 CD and 40 ITB); step 2, development of a new prediction model using laboratory and radiologic parameters combined with the colonoscopic scoring system (the development group; 40 CD and 40 ITB); step 3, validation of the new prediction model (the validation group; 14 CD and 23 ITB). To limit the number of variables and to maximize the clinical applications, only objective parameters easily available at the time of initial evaluation were selected. Therefore, symptoms and pathologic parameters were excluded when building the prediction model. This study was reported according to the STARD and TRIPOD guidelines (see Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B525), and it was registered at www.clinicaltrials.gov (NCT01392365). 11, 12 
Colonoscopic Evaluation
Colonoscopies were performed by 2 endoscopists (B.D.Y and S.H.P) using a single-channel endoscope (CF-H260AL; Olympus Co., Tokyo, Japan) according to the study protocol (see Fig. S2 , Supplemental Digital Content 2, http://links.lww.com/IBD/B526). During the colonoscopy, the endoscopic characteristics of CD and ITB were carefully observed and recorded in the case report form (see Fig. S3 , Supplemental Digital Content 3, http://links. lww.com/IBD/B527). Based on the previous colonoscopic scoring system described by Lee et al, 7 8 endoscopic parameters for differentiation between the 2 diseases were recorded at the time of colonoscopy. We assigned a score of +1 to the 4 colonoscopic parameters that are characteristic of CD (anorectal lesions, longitudinal ulcers, aphthous ulcers, and cobblestone appearance), and 21 to the other 4 parameters that are indicative of ITB (involvement of fewer than 4 segments, a patulous ileocecal valve, transverse ulcers, and scars or pseudopolyps). 7 We diagnosed the patient with CD when the sum of the scores for the 8 parameters was greater than zero and with ITB when the sum was less than zero; the diagnosis was regarded as indeterminate when the score was zero (Fig. 1) . 7 
Laboratory Evaluation
The following laboratory tests were performed in all patients: complete blood count, chemistry, erythrocyte sedimentation rate (ESR), anti-Saccharomyces cerevisiae antibodies (ASCAs) IgA and IgG, and QuantiFERON-TB Gold In-Tube Test (QFT-G). Leukocytosis was defined as a leukocyte count .10,000/mm 3 , and anemia was defined as a hemoglobin concentration ,13 g/dL (men) or ,12 g/dL (women). Hypoalbuminemia was defined as an albumin level ,3.5 g/dL, and an elevated ESR was defined as an ESR .20 mm/h. ASCA IgA and IgG were quantified using standard calibrated enzymelinked immunosorbent assay commercially available kits, and the tests were performed according to the manufacturer's instructions (QUANTA Lite; INOVA Diagnostics, San Diego, CA). Results of ASCA IgA and IgG testing were classified as negative (0.0-20.0 units), equivocal (20.1-24.9 units), or positive ($25 units). Positive ASCA was further classified as ASCA IgG-positive and/or IgA-positive. The QFT-G (Cellestis Ltd., Victoria, Australia) was performed according to the manufacturer's instructions, and a positive value of 0.35 IU/mL of interferon-g was used as the cutoff. 13 
Histologic Evaluation and Mycobacterial Culture
Multiple biopsy specimens were obtained from all patients with abnormal lesions, using standard colonoscopic biopsy forceps. Biopsy was performed from more than 1 lesion per segment with lesions and more than 2 pieces per lesion. All specimens were fixed with 10% formaldehyde and were evaluated under light microscopy with standard hematoxylin and eosin staining. They were also stained using the Ziehl-Neelsen method for AFB detection. Mycobacterial culture using minimum 3 pieces of colonoscopic biopsy specimens was performed using both 2% Ogawa medium (Korean Institute of Tuberculosis, Seoul, Korea) and BACTEC Mycobacteria Growth Indicator Tube (MGIT, BD, Franklin Lakes, NJ) as previously described in detail. 14 The Ogawa and MGIT media were incubated for up to, respectively, 8 and 6 weeks. 14 Positive MGIT media or colonies on Ogawa medium were subjected to Ziehl-Neelsen staining and PCR assay using Seeplex TB detection (Seegen, Seoul, Korea) and Myco-ID (M&D, Wonju, Korea) to differentiate between MTB and nontuberculous mycobacteria. 14 
Radiologic Evaluation
Chest x-ray (CXR) and small bowel follow through (SBFT) were performed in all patients. Findings of CXR were defined as positive if the CXR was highly consistent with the typical features of pulmonary TB such as patchy or nodular shadows, cavitations, and calcified shadows. 15 SBFT was performed using a 22.5% wt/vol barium suspension prepared in a 0.5% methylcellulose solution containing methylcellulose and barium sulfate powder. 16 The small intestine was divided into 2 segments (proximal intestine and terminal ileum). The terminal ileum was defined as the 20 cm segment of ileum nearest to the ileocecal valve. 16 Findings of the SBFT were defined as positive if the SBFT images showed evidence of inflammation such as aphthous lesions, fold thickening, ulcers, or a cobblestone pattern in the proximal intestine segment.
Statistical Analysis
The number of enrolled cases per disease was estimated for the current study. Thirty-five subjects were needed in each disease group to achieve a statistical power of 90% with a significance level of 5% when the area under the curve was 0.8 and 0.6 in the null hypothesis. We anticipated a 10% dropout rate and finally enrolled a total of 80 patients (40 patients per group) for the development group. The association between the study variables and the type of disease (CD or ITB) was assessed using the chi-square test and odds ratios with 95% confidence intervals (CIs). All laboratory and radiologic parameters showing statistical significance (P , 0.05) were taken as candidates for multivariate logistic regression analyses.
Placement into the 3 categories, ITB, CD, or indeterminate, was determined by summing the selected laboratory and radiologic parameters. The new prediction score was constructed by adding the laboratory-radiologic score to the colonoscopic score. Receiver operating characteristic (ROC) analysis was performed on the new scores to assess the ability to discriminate between CD and ITB. To estimate the probability of predicting either ITB or CD, logistic analysis was completed using these scores. The developed score was validated based on consecutively collected data from 37 new patients who were suspected of having either CD or ITB. Analyses were performed with the statistical software package SPSS 21.0 (SPSS Inc., Chicago, IL) and R 3.1.1.
RESULTS
Baseline Characteristics
A total of 100 patients were screened for the development of the prediction model. Of those, 20 patients were excluded because of a diagnosis other than CD or ITB (n ¼ 8; intestinal Behçet's disease, 3; self-resolving nonspecific ulcerative lesions, 3; ulcerative colitis, 1; and nonsteroidal anti-inflammatory drugrelated colonic lesions, 1), refusal to participate in the study (n ¼ 5), history of previous medication (n ¼ 5; corticosteroids, 3; anti-TB therapy, 1; chemotherapy for cancer, 1), or inadequate data collection (n ¼ 2). The remaining 80 patients (40 patients with CD and 40 with ITB) were finally enrolled and analyzed for the development group (Fig. 2) . The final diagnostic criteria for ITB were as follows; (1) positive culture of MTB (23 patients, 57.5%), (2) positive culture of MTB + AFB smear (2 patients, 5.0%), (3) positive culture of MTB + caseating granuloma (2 patients, 5.0%), (4) positive AFB smear (1 patient, 2.5%), (5) positive culture of MTB + AFB smear + caseating granuloma (1 patient, 2.5%). The remaining 11 patients (27.5%) were diagnosed with ITB based on positive responses to anti-TB treatment without subsequent recurrence, a method applied in our previous studies. 7, 14 The additional information for clinical symptoms and histopathologic features in the development group is shown in Table S1 (see Supplemental Digital Content 4, http://links.lww.com/IBD/B528).
For the validation of the prediction model, another 38 patients were screened, and 1 patient was excluded because the diagnosis changed from CD to intestinal Behçet's disease during the follow-up. Therefore, a total of 37 patients (14 CD and 23 ITB) were enrolled and analyzed in the validation group. Of the 23 patients with ITB in the validation group, the final diagnostic criteria for ITB were as follows; (1) Table 1 .
Colonoscopic Scoring
The colonoscopic findings of each disease in the development group are summarized in Table 2 . The diagnosis of either CD or ITB in the development group was correct in 65 patients (81.2%), incorrect in 7 patients (8.8%), and could not be determined in 8 patients (10%) (see Table S2 , Supplemental Digital Content 4, http://links.lww.com/IBD/B528). The sensitivity of the colonoscopic scoring system was 65.0% (26/40) for CD and 97.5% (39/40) for ITB.
Differential Features in Laboratory and Radiologic Parameters
Univariate and Multivariate Analyses of Laboratory and Radiologic Parameters
In the analysis of laboratory parameters, anemia, hypoalbuminemia, elevated ESR, and positive ASCA were significantly more common in patients with CD than in patients with ITB (Table 3) . Positive QFT-G was significantly more common in patients with ITB than in those with CD (Table 3) . Positive ASCA and positive QFT-G were found to be independent laboratory parameters for distinguishing between the 2 diseases through multivariate logistic regression analysis (Table 3) . For radiologic parameters, both involvement of the proximal intestine on SBFT and typical pulmonary TB findings on CXR were found to be independent radiologic parameters for discrimination with multivariate logistic regression analysis (Table 3) .
Diagnostic Values of Laboratory and Radiologic Parameters in Combination with Colonoscopic Parameters
Using the same method as the colonoscopic scoring system, we assigned a score of +1 to 2 laboratory-radiologic parameters typical of CD (positive ASCA and involvement of the proximal intestine) and 21 to the other 2 parameters for ITB (positive QFT-G and typical pulmonary TB findings). The diagnosis of either CD or ITB in the development group was correct in 58 patients (72.5%), incorrect in 1 patient (1.2%), and could not be made in 21 patients (26.3%) (see Table S3 , Supplemental Digital Content 4, http://links.lww.com/IBD/B528). The sensitivity of laboratory-radiologic scoring was 70.0% (28/40) for CD and 75.0% (30/40) for ITB. The discriminant ability of the colonoscopic scoring system as determined by the area under the ROC (AUROC) curve was 0.908 (95% CI, 0.835-0.981). When laboratory-radiologic scoring was added to colonoscopic scoring, the AUROC increased to 0.990 (95% CI, 0.975-1.000).
Development of a New Prediction Model Combining Colonoscopic Scoring with Laboratory-Radiologic Scoring
Based on the results of both colonoscopic and laboratory-radiologic scoring, we developed a new prediction model. In each colonoscopic scoring and laboratory-radiologic scoring system, the sum of the parameters was calculated. The attributed scores were 21 point for a negative score, 0 points for a zero score, and +1 point for a positive score. The new score was made by adding the colonoscopic score (from 21 to +1) and the laboratory-radiologic score (from 21 to +1) and consequently ranged from 22 to +2. After using the new scoring system to differentiate between the 2 diseases, significant trends emerged as increasing score values predicted CD, and this score was termed the CD prediction score (CDS) (Fig. 3) . When the cutoff score for CD was set to be 0 or above, the accuracy of CDS was 96.3% (77/ 80) with a sensitivity of 95.0% (38/40) for CD and a CD positive predictive value of 97.4% (38/39). The sensitivity of CDS for ITB was 97.5% (39/40), and the positive predictive value was 95.1% (39/41). The diagnostic performance of all scoring systems is shown in Table 4 .
Validation of the CD Prediction Score
The distribution of the colonoscopic and laboratory-radiologic score in the validation group was shown in Tables S4 and S5 (Supplemental Digital Content 4, http://links.lww.com/IBD/B528), respectively. In the validation group, a CDS of 22 or 21 accurately identified patients with ITB without any misclassifications (Fig. 3) . The proportion of the 2 diseases in the validation group as determined by the CDS was similar to that in the development group. The overall discriminant ability of the model in the validation group as determined by the AUROC curve was 0.981 (95% CI, 0.947-1.000) as opposed to 0.990 (95% CI, 0.975-1.000) in the development group (Fig. 4) .
Scheme to Define CD Prediction Score
Based on the CDS, we proposed a probability of CD prediction using logistic regression. The scores were categorized into 5 groups based on the probability of CD: very low (CDS: 22, 0.3%), low (CDS: 21, 14.9%), moderate to high (CDS: 0, 90.4%), high (CDS: 1, 99.8%), and very high (CDS: 2, 100%). The key results of this study are summarized schematically in Figure 5 .
DISCUSSION
In Korea, where ITB is prevalent and CD incidence is rising, 40% to 47% of patients with CD were reported to have received a therapeutic trial of anti-TB drugs before diagnosis with CD. 17, 18 Likewise, 54% to 65% of patients with CD were misdiagnosed as having ITB in studies from China. 19, 20 Anti-TB therapeutic trial has been used as a part of a differential diagnosis algorithm between CD and ITB in countries with a high prevalence of TB, 2,21 but sideeffects of anti-TB therapy include significant adverse events and morbidity. 22 Furthermore, the emergence of multidrug-resistant TB may limit the benefits of using the response to first-line anti-TB drugs as a way of establishing ITB diagnosis, and it can cause a delay in the management of patients with CD. 22, 23 Therefore, a more accurate and safe diagnostic tool is required to replace the past strategy of relying on anti-TB medication. Using our new prediction model, we were able to distinguish CD from ITB with a very high-discriminant power in both the development and the validation groups (over 0.98 of AUROC).
For colonoscopic evaluation, we applied the scoring system from our previous study and validated it. 7 Although all 8 colonoscopic parameters are still discriminate between CD and ITB, the overall accuracy of the colonoscopic scoring system was 78.6% (92/117; 65/80 in the development group and 27/37 in the validation group), about 10% lower than our previous report (87.5%, 77/88). Similarly, another study from China using the same colonoscopic scoring system also showed a lower overall accuracy (66.7%, 70/105) than the original study. 7, 24 The lower accuracy of colonoscopic scoring might be explained in several ways. First, when building the colonoscopic scoring system in the previous study, 7 only patients presenting with overt lesions in the colonoscopy were selected. By contrast, we enrolled 8 CD patients with lesions confined to the terminal ileum or without any active lesions in the colonoscopy, based on laboratory and radiologic findings. With the colonoscopic scoring system, those patients were misdiagnosed with ITB (n ¼ 7) or classified as indeterminate (n ¼ 1), thereby lowering the accuracy of the colonoscopic diagnosis. Second, patients with milder or earlier stages of CD or ITB might have been enrolled in the current study. The proportion of the colonoscopic finding showing mild features, such as involvement of fewer than 4 segment, was higher in the current study than in the previous study (57.5% versus 18.2% in CD and 97.5% versus 81.8% in ITB). 7 During the past 10 years, screening colonoscopies and awareness of inflammatory bowel diseases have significantly increased in Korea. Therefore, enrollment of cases with shorter durations or in the mild stages of disease before presentation of advanced colonoscopic features might result in a lower discriminant power of colonoscopy.
On investigation of laboratory parameters, ASCA positivity was selected to build the current prediction model. Positive ASCA was significantly higher in patients with CD than ITB (60.0% versus 7.5%, respectively). ASCAs have been shown to be strongly associated with the inflammatory processes of the intestine and were used as a marker for CD; healthy family members of patients with CD were often positive for ASCA. [25] [26] [27] Recently, several studies have evaluated the utility of ASCA for differentiating between CD and ITB, but the utility of ASCA is controversial. [28] [29] [30] [31] [32] Although the exact reasons for this discrepancy are still unclear, it can be explained by a following hypothesis. Several studies have suggested an association between ASCA positivity and increased intestinal permeability; therefore, any condition that increases the transport of food antigens across the intestinal mucosa may result in a positive ASCA test result. 33, 34 Consequently, ASCA positivity in ITB may vary depending on the intestinal permeability based on the severity of mucosal inflammation. In the current study, the median duration of symptoms in patients with ITB in the development group was only 3.5 months, and 35.0% (14/40) of patients with ITB did not show any symptoms at diagnosis. However, other studies showing high ASCA positivity in patients with ITB often showed overt clinical symptoms such as abdominal pain and weight loss, and high levels of inflammatory makers, such as C-reactive protein and ESR. 1, 30 Therefore, the varying extent or severity of ITB seems to result in the differences in ASCA positivity from study to study, and we presume that ASCAs have differential diagnostic value in cases of the mild or early stage of ITB. Recently, various types of modality such as magnetic resonance enterography (MRE), computerized tomography enterography (CTE), capsule endoscopy, and SBFT are being used for the evaluation of small bowel disorders. Each procedure has its own pros and cons on the radiation dose and cost. Especially, patients with CD are often young and CD has a chronic relapsing disease course, leading to expose to a high cumulative lifetime radiation dose. Also, most TB-prevalent countries are usually still developing, and diagnostic modalities such as CTE or MRE are not so popular in those countries. Therefore, we used SBFT for small bowel evaluation because SBFT has been the standard radiologic approach for small bowel disorders for a long time, and the radiation dose of SBFT is approximately 70% less compared with CT. 35 In addition, the cost of SBFT is much lower than CTE or MRE in Korea. Regarding diagnostic accuracy, a study comparing the accuracy of CTE, MRE, and SBFT for detecting active small bowel inflammation in patients with CD found that 3 modalities were comparable. 16 In our study, patients with CD had proximal intestinal involvement (55.0%) more frequently than patients with ITB (10.0%). This result was consistent with a previous study using CTE (29.9% in CD versus 5.3% in ITB). 24 CD is known to involve any part of the intestine by immunologic reaction with intestinal flora, whereas MTB usually shows preference for lymphocytes or Peyer's patches, which are abundant in the terminal ileum. 36, 37 This might explain why CD usually shows more extensive lesions compared with ITB.
Our study has several strengths. First, we prospectively enrolled new patients who had never been diagnosed with or treated for CD or ITB. Moreover, we excluded patients with medication histories that could have influenced the expression or severity of the diseases. We also performed elaborate histologic and microbiological evaluations in all enrolled patients, and the final diagnosis of ITB could be confirmed with histology and/or microbiological evidence in most patients (76.2%, 48/63). In addition, the differential diagnosis between CD and ITB was provided by a simple predictive score with a very high power of discrimination. However, the current study also has potential limitations. This study was a single center-based study, and a validation in multiple centers would have been better for confirming the usefulness of our model. However, the residing addresses of 117 study participants were distributed throughout Korea, meaning that this study was not limited to a specific population group. Certain parameters in our model, including colonoscopic parameters and ASCA, might result in different findings in other countries with different epidemiological backgrounds. However, each colonoscopic and laboratory-radiologic scoring in our model showed a complementary role for differentiating between CD and ITB. Therefore, further external validation in other population is needed for confirming the clinical value of our model. In summary, the correct diagnosis of CD or ITB can be made in most patients when the diagnosis for colonoscopic parameters is complemented by laboratory and radiologic findings through the use of ASCA, QFT-G, CXR, and SBFT. The new prediction model using CDS can aid in making a fast and accurate diagnosis of either ITB or CD at the initial evaluation and may reduce the inappropriate use of anti-TB therapy in patients with CD and immunosuppressants in patients with ITB.
